Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (Q85006337)

From Wikidata

Jump to navigation Jump to search

scientific article published on 09 September 2010

Language	Label	Description	Also known as
English	Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor	scientific article published on 09 September 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20828860%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20828860%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

non-small-cell lung carcinoma

1 reference

based on heuristic

inferred from title

author name string

Isamu Okamoto

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20828860%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Toshiaki Takahashi

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20828860%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Hiroaki Okamoto

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20828860%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Kazuhiko Nakagawa

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20828860%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Koshiro Watanabe

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20828860%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Kiyoshi Nakamatsu

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20828860%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Yasumasa Nishimura

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20828860%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Masahiro Fukuoka

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20828860%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Nobuyuki Yamamoto

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20828860%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20828860

9 July 2024

publication date

9 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20828860%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

full work available at URL

https://api.elsevier.com/content/article/PII:S0169500210004241?httpAccept=text/xml

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

https://api.elsevier.com/content/article/PII:S0169500210004241?httpAccept=text/plain

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20828860%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

72

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20828860%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20828860%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

199-204

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20828860%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Cancer statistics, 2009

1 reference

28 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.3322/CAAC.20006

Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer

2

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

3

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer

4

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan

5

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

The epidermal growth factor receptor mediates radioresistance.

6

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Epidermal growth factor receptor and its inhibition in radiotherapy:in vivofindings

7

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development

8

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation

9

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization

10

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).

11

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers

14

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy

15

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Overview of gefitinib in non-small cell lung cancer: an Asian perspective

16

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Reasons for response differences seen in the V15-32, INTEREST and IPASS trials

17

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

18

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

19

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

20

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

22

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study

23

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-sm

24

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer

25

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer

26

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

27

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

28

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp

29

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer

30

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy

31

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).

32

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

33

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations

34

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.

35

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

36

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

37

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

38

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Cranial prophylactic irradiation in locally advanced non-small cell lung carcinoma: current status and future perspectives.

39

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation.

40

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

41

1 reference

10.1016/J.LUNGCAN.2010.08.016

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.016

9 July 2024

Identifiers

10.1016/J.LUNGCAN.2010.08.016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20828860%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20828860%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q85006337&oldid=2199822808"